GH1 and Creutzfeldt Jacob disease: The incidence curves of hGH- and hDM-associated CJD exhibiting a broad peak occurred in the mid-to-late 1990s [11], when the implementation of both hGH and hDM grafts was ceased and replaced with recombinant pituitary hormones and dura substitutes (synthetic or derived from non-human animals), respectively.